# Neil Ray

> Neil P. Ray, MD is a board-certified pediatric anesthesiologist who traded the operating room for a startup. As founder and CEO of Raydiant Oximetry, he is building Lumerah, a non-invasive fetal pulse oximeter that reads a baby's oxygen levels through the mother's abdomen, and Daisy, a surgical device to prevent postpartum hemorrhage. His goal: retire a 50-year-old fetal monitor he calls no better than a coin toss, and cut the number of unnecessary C-sections that follow from it.

- **Role:** Founder & CEO at Raydiant Oximetry, Inc.
- **Organizations:** Raydiant Oximetry, Inc., Fogarty Institute for Innovation
- **Nationality:** American
- **Education:** B.A., Mathematics, Northwestern University, M.D., Rush Medical College, Residency, Anesthesiology, Harvard Medical School
- **Known for:** Founded and leads Raydiant Oximetry, developing Lumerah and Daisy for maternal and fetal safety, Lumerah earned FDA Breakthrough Device designation and Investigational Device Exemption approval, Raised more than $31M in total funding, including an oversubscribed $7.5M Series A extension in 2024

## Career timeline

- **2005** — Begins practicing as a board-certified pediatric anesthesiologist
- **2016** — Founds Raydiant Oximetry, Inc. to build a better fetal pulse oximeter
- **2022** — Company reports roughly $10M invested, five years into a ~10-year, ~$30M development plan
- **2024** — Closes oversubscribed $7.5M Series A extension; first participants enrolled in Lumerah and Daisy clinical studies
- **2025** — Announces joint development initiative with GE HealthCare for fetal oxygen saturation technology

## Achievements

- Founded and leads Raydiant Oximetry, developing Lumerah and Daisy for maternal and fetal safety
- Lumerah earned FDA Breakthrough Device designation and Investigational Device Exemption approval
- Raised more than $31M in total funding, including an oversubscribed $7.5M Series A extension in 2024
- Won multiple SBIR awards from the National Science Foundation and National Institutes of Health
- Secured a joint development initiative with GE HealthCare in 2025
- Selected into the Fogarty Institute for Innovation medical device accelerator

## Latest updates

- **2025-05** — Raydiant Oximetry and GE HealthCare announced a joint development initiative to integrate fetal pulse oximetry into GE's fetal monitoring platforms.
- **2024-06** — Closed an oversubscribed $7.5M Series A extension led by Cross-Border Impact Ventures.
- **2024-05** — First participants enrolled in clinical studies for Lumerah and Daisy at Eastern Virginia Medical School.

## Links

- Website: https://raydiantoximetry.com
- LinkedIn: https://www.linkedin.com/in/neilpray
- Twitter/X: https://twitter.com/RaydiantSpO2
- Facebook: https://facebook.com/RaydiantOximetry/

---

Profile page: https://yespress.io/neil-ray
Published by YesPress — https://yespress.io
Last updated: 2026-07-01